 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
At time of writing, Research Associate, Center for Drug Information and Pharmacy Practice, ABDA—Federal Union of German Associations of Pharmacists, Berlin, Germany
Head, Center for Drug Information and Pharmacy Practice, ABDA; Adjunct Professor, Department of Pharmacology, Johann Wolfgang Goethe-University, Frankfurt at Main, Germany
Professor, Institute of Clinical Psychology, Technical University of Chemnitz, Germany
Senior Research Associate, Primary Health Care Research Group, Department of Child and Adolescent Psychiatry, University of Cologne, Cologne, Germany
Head, Primary Health Care Research Group, Department of Child and Adolescent Psychiatry, University of Cologne
Biostatistician and Head, MSB Statistical Consulting, Bremen, Germany
Reprints: Dr. Schulz, Center for Drug Information and Pharmacy Practice (ZAPP), ABDA—Federal Union of German Associations of Pharmacists, Jaegerstrasse 49/50, 10117 Berlin, Germany, fax 49 30/40004 243, M.Schulz{at}abda.aponet.de
BACKGROUND: Despite significant progress in asthma drug therapy in recent years, there has been no major change in asthma morbidity and mortality. It is still important to determine whether pharmaceutical care (PC) influences health outcomes.
OBJECTIVE: To evaluate the effectiveness of PC with regard to clinical, humanistic, and economic outcomes in adults with asthma.
METHODS: An intervention study was conducted over 12 months. At baseline, 39 community/retail pharmacies, 84 primary care physicians (general practitioners, internal specialists, chest physicians), and 183 patients (aged 18-65 y) diagnosed with asthma were included. To evaluate economic outcomes, 2 German statutory health insurance funds provided 2 years of claims data for their insured patients (n = 55). A 1:10 matching was carried out to compare the data of this intervention subgroup with those of a control group (n = 550).
RESULTS: Significant improvements were found for all humanistic outcomes (eg, asthma-specific quality of life, self-efficacy, knowledge, medication adherence). In addition, asthma severity, self-reported symptoms, peak expiratory flow, and patients' inhalation technique improved. Increases in forced expiratory volume in 1 second and vital capacity were not significant over time. Evaluation of the insurance claims data revealed a shift toward better adherence to evidence-based therapy.
CONCLUSIONS: The study shows that PC for people with asthma has a positive impact on humanistic and, to some extent, on clinical outcomes. To determine potential economic benefits, future research should focus on patients with more severe asthma.
Key Words: asthma, community pharmacy, pharmaceutical care, pharmacy practice
Published Online, October 11, 2005. www.theannals.com, DOI 10.1345/aph.1G180
This article has been cited by other articles:
|
|
 |
|
  E. Mehuys, L. Van Bortel, L. De Bolle, I. Van Tongelen, L. Annemans, J. P. Remon, and G. Brusselle Effectiveness of pharmacist intervention for asthma control improvement Eur. Respir. J., April 1, 2008; 31(4): 790 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Dib and S. A. Abdulmohsin Establishing a pharmaceutical care clinic in a Saudi Arabian health center Am. J. Health Syst. Pharm., January 1, 2007; 64(1): 107 - 109. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Eickhoff and M. Schulz Pharmaceutical Care in Community Pharmacies: Practice and Research in Germany Ann. Pharmacother., April 1, 2006; 40(4): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
